Cartesian Therapeutics Inc (RNAC)
Stock-Based Compensation
$2.08M
Quarterly · Period ending: · USD
RNAC Stock-Based Compensation
Latest reported$2.08Mperiod ending
Latest reported$2.08Mperiod ending
RNAC Quarterly Stock-Based Comp ($302.00K → $2.08M)
Quarterly stock-based compensation
High-resolution chart · PNG
RNAC stock-based compensation history
Quarterly · USD. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | Stock-Based Compensation (USD) |
|---|---|
| 2,083,000 | |
| 2,423,000 | |
| 2,144,000 | |
| 2,590,000 | |
| 3,279,000 | |
| 2,508,000 | |
| 1,865,000 | |
| 1,695,000 | |
| 1,591,000 | |
| 1,431,000 | |
| 17,398,000 | |
| 2,321,000 | |
| 3,783,000 | |
| 2,276,000 | |
| 2,276,000 | |
| 2,601,000 | |
| 3,564,000 | |
| 2,753,000 | |
| 2,253,000 | |
| 1,904,000 | |
| 1,783,000 | |
| 1,780,000 | |
| 1,236,000 | |
| 1,296,000 | |
| 1,481,000 | |
| 1,409,000 | |
| 1,427,000 | |
| 1,303,000 | |
| 1,251,000 | |
| 1,180,000 | |
| 1,790,000 | |
| 1,485,000 | |
| 1,286,000 | |
| 1,153,000 | |
| 1,209,000 | |
| 1,314,000 | |
| 865,000 | |
| 693,000 | |
| 770,000 | |
| 632,000 | |
| 367,000 | |
| 282,000 | |
| 256,000 | |
| 252,000 | |
| 315,000 | |
| 302,000 |